Xenetic Biosciences, Inc. XBIO 深 滬
已收盤 08-01 16:00:00 美东时间
3.215
-0.025
-0.77%
華盛通- 最 高3.4299
- 今 開3.18
- 成交量 2.13万股
- 最 低 3.05
- 昨 收 3.24
- 總市值 495.79万
- 52周最高 5.2683
- 市盈率 靜 --
- 換手率 1.38%
- 52周最低 2.20
- 委 比 -89.69%
- 總股本 154.21万
- 歷史最高 1074.00
- 量 比 0.20
- 振 幅 11.73%
- 歷史最低 2.20
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Xenetic Biosciences Announces First Patient Dosing In Exploratory Clinical Study Of Systemic DNase I In Combination With FOLFIRINOX For Advanced Or Metastatic Pancreatic Cancer
Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNessCompany evaluating systemic recombinant human DNase I (DNase I) in combination with
07-08 21:04
抢滩华贸黄金地段 迪桑特想复刻始祖鸟
转自：北京商报 高端运动品牌迪桑特在华迈出关键一步。北京商报记者从华贸中心处获悉，迪桑特已正式接手北京华贸中心原阿玛尼旗舰店1400平方米黄金铺位，创下...
06-20 00:29
Xenetic Biosciences reports Q1 results
Xenetic Biosciences press release (NASDAQ:XBIO): Q1 Net loss was approximately $0.9 million. Revenue increased by approximately $0.1 million, or 16.1%, to approximately $0.6 million during the three m...
05-14 20:21
Xenetic Biosciences Q1 EPS $(0.59) Beats $(0.72) Estimate, Sales $593.26K Miss $670.00K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.72) by 18.06 percent. This is a 24.36 percent increase over losses of $(0.78) per share
05-14 05:58
Xenetic Biosciences Net Loss For The Year Ended December 31, 2024 Was ~$4M; Ended The Year With ~$6.2M Of Cash
Summary of Financial Results for Fiscal Year 2024Net loss for the year ended December 31, 2024 was approximately $4.0 million. Research and development expenses for the year ended December 31, 2024 decreased by
03-19 20:20
失去始祖鸟代理权 三夫户外自救
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：北京商报 失去始祖鸟代理权或许还不算太糟糕，但失去代理权后始祖鸟的...
01-08 23:30
纺织服饰行业周报：NIKE FY25Q2业绩超市场预期
主要观点 本周Nike 发布FY25Q2（截至24/11/30）业绩，收入同比下滑 8%至 124 亿美元（货币中性口径下滑 9%），净利润同比下滑 26%至...
2024-12-21 00:00
Xenetic Biosciences Q3 EPS $(0.28) Misses $(0.20) Estimate, Sales $614.24K Beat $230.00K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.20) by 40 percent. This is a 59.42 percent increase over losses of $(0.69) per share
2024-11-13 21:34
Xenetic Biosciences Expands Collaboration for Cancer Treatment
Xenetic Biosciences ( ($XBIO) ) just unveiled an update. Xenetic Biosciences ha...
2024-11-07 22:28
Next Science Ltd: Innovations in Healthcare Market
Next Science Ltd (AU:NXS) has released an update. Next Science Ltd is making st...
2024-10-24 08:40
